卵巢透明细胞癌:流行病学、病理生物学特征、治疗选择与临床结局
本文综述卵巢透明细胞癌的流行病学、病理及生物学特征、治疗选择和临床结局。该病为罕见独特的上皮性卵巢癌亚型,患者通常较年轻且分期较早,子宫内膜异位症是主要危险因素并被视为前驱病变,超过50%患者中可识别。早期预后良好,晚期或复发者肿瘤结局差,因内在化疗耐药应答率低,晚期治疗仿照高级别浆液性癌,采用积极肿瘤细胞减灭术和铂类化疗。
要点
- 透明细胞癌患者通常比高级别浆液性癌患者更年轻且诊断时分期更早。
- 子宫内膜异位症是主要危险因素,在超过50%的透明细胞癌患者中可识别为前驱病变。
- 早期预后良好,晚期或复发者肿瘤结局差,因内在化疗耐药应答率较低。
核心结论
- 卵巢透明细胞癌是罕见且独特的上皮性卵巢癌组织学亚型,早期预后良好而晚期或复发者肿瘤结局差。
研究设计与样本
- 本文为综述,总结卵巢透明细胞癌的流行病学、病理和生物学特征、治疗选择及临床结局。
主要发现
- 透明细胞癌患者通常比高级别浆液性癌患者更年轻且诊断时分期更早。
- 子宫内膜异位症被视为透明细胞癌的主要危险因素和前驱病变,在超过50%的患者中可识别。
- 已鉴定出ARID1A和PIK3CA等常见突变及不同分子通路改变。
- 早期患者预后良好,晚期或复发患者肿瘤结局差,因内在化疗耐药应答率较低。
关键数值与推荐
- 晚期疾病治疗策略类似高级别浆液性癌,包括积极肿瘤细胞减灭术和铂类化疗。
- 完全手术分期的I期患者辅助化疗的作用仍在讨论中。
临床怎么用
- 晚期透明细胞癌按高级别浆液性癌模式行积极肿瘤细胞减灭术和铂类化疗。
- I期完全手术分期患者的辅助化疗决策需权衡,因作用尚存争议。
- 靶向不同通路的生物制剂是有前景的替代治疗策略,需国际协作试验验证。
局限性
- 本文为综述,未报告原始研究的具体样本量、效应量或置信区间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clear cell carcinoma of the ovary is a rare and distinct histotype of epithelial ovarian carcinomas. Women diagnosed with clear cell carcinomas are usually younger and diagnosed at earlier stages than those with the most common high-grade serous histology. Endometriosis is considered a main risk factor for the development of clear cell carcinoma of the ovary, and it can be considered a precursor of of this tumor, as it is identified in more than 50% of patients with clear cell carcinoma. Different molecular pathways and alterations heve been identified in ovarian clear cell carcinoma, including the most common mutations of AT-rich interaction domain 1A [ARID1A] and phosphatidylinositol-4,5-bisphosphate 3-kinase [PIK3] catalytic subunit alpha [PIK3CA]. The prognosis of patients at early stage is favorable, while patients with advanced or recurrent disease experience a poor oncologic outcomes. Despite a lower rate of responses due to an intrinsic chemoresistance, the treatment strategy for advanced disease resembles the treatment of high-grade serous carcinoma, which includes aggressive cytoreductive surgery and platinum-based chemotherapy. For this reason, the role of adjuvant chemotherapy in patients with stage I disease undergoing complete surgical staging is still under debate. Alternative treatments, including biological agents that target different pathways constitute the most promising treatment strategies, and well-designed, collaborative international trials should be designed in order to improve the oncologic outcomes and the quality of life of patients with this aggressive disease.
引用
- Gadducci A, Multinu F, Cosio S, et al. Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes. Gynecol Oncol. 2021. PMID: 34247767. doi:10.1016/j.ygyno.2021.06.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。